Asakura and colleagues demonstrated that blocking PD-L1 antibody treatment early after allo-HCT improved T cell effector functions and GVL activity in mice, but this occurred at the expense of aggravated GVHD (50). The gene discussed is CD274; the disease is graft versus host disease.